BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells

被引：0
作者：
Amy E. Campbell
Jonathan Oliva
Matthew P. Yates
Jun Wen Zhong
Sean C. Shadle
Lauren Snider
Nikita Singh
Shannon Tai
Yosuke Hiramuki
Rabi Tawil
Silvère M. van der Maarel
Stephen J. Tapscott
Francis M. Sverdrup
机构：
[1] Fred Hutchinson Cancer Research Center,Human Biology Division
[2] Saint Louis University,Edward A. Doisy Department of Biochemistry and Molecular Biology
[3] University of Washington,Molecular and Cellular Biology Program
[4] University of Rochester Medical Center,Department of Neurology
[5] Leiden University Medical Center,Department of Human Genetics
[6] University of Washington,Department of Neurology
来源：
Skeletal Muscle | / 7卷
关键词：
Facioscapulohumeral muscular dystrophy; FSHD; DUX4; Bromodomain; Adrenergic; High-throughput screening;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 2 条
  • [1] BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
    Campbell, Amy E.
    Oliva, Jonathan
    Yates, Matthew P.
    Zhong, Jun Wen
    Shadle, Sean C.
    Snider, Lauren
    Singh, Nikita
    Tai, Shannon
    Hiramuki, Yosuke
    Tawil, Rabi
    van der Maarel, Silvere M.
    Tapscott, Stephen J.
    Sverdrup, Francis M.
    SKELETAL MUSCLE, 2017, 7
  • [2] Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells
    Sarsons, Christopher D.
    Gilham, Dean
    Tsujikawa, Laura M.
    Wasiak, Sylwia
    Fu, Li
    Rakai, Brooke D.
    Stotz, Stephanie C.
    Carestia, Agostina
    Sweeney, Michael
    Kulikowski, Ewelina
    BIOMEDICINES, 2023, 11 (10)
1